RxDoctor Payments Data

Kelly Walton

Family · Tacoma, WANPI 1417734963

Payments from drug & device makers

$810in general payments, 2019–2025

Across 26 payments — averaging $31.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kestra Medical Technology Services, Inc.$205
  • Abbott$133
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$104
  • Novartis$76
  • Merck$56
  • Baxter Healthcare$46
  • plus $190 from 8 others

What the payments were for

  • Food & beverage$810100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$810 in reported general payments places this provider in the 75th percentile of 1,706 family providers in Washington.

See all family providers in Washington

Medicare billing

Part B allowed, 2024
$37,382
Medicare patients
183
Services billed
417

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin112$121,184
EntrestoSacubitril/Valsartan96$95,346
FarxigaDapagliflozin Propanediol31$30,807
EliquisApixaban19$17,233
Torsemide108$2,458
Bumetanide32$1,900
Potassium Chloride92$1,662
Metoprolol Succinate80$1,131
Spironolactone108$734
Isosorbide Dinitrate14$702
Eplerenone15$631
Hydralazine Hcl32$553
Bisoprolol Fumarate18$537
Valsartan17$503
Furosemide84$375

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$22$121,184112 claims
NovartisEntresto$76$95,34696 claims
AstraZenecaFarxiga$19$30,80731 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,706 family providers in Washington.

Other family in Tacoma

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →